Table 1 Patient demographics and baseline characteristicsa
From: Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial
Demographics and characteristics | Placebo (n= 50) | Milnacipran (n= 100) | Total (N= 150) |
|---|---|---|---|
Mean age (SD), years | 54.0 (8.3) | 54.5 (9.3) | 54.3 (9.0) |
Women, n (%) | 48 (96.0) | 96 (96.0) | 144 (96.0) |
Race, n (%) | Â | Â | Â |
   White | 47 (94.0) | 96 (96.0) | 143 (95.3) |
   Nonwhite | 3 (6.0) | 4 (4.0) | 7 (4.7) |
Mean weight (SD), kg | 77.3 (16.7) | 80.2 (14.5) | 79.2 (15.3) |
Mean body mass index (SD), kg/m2 | 29.0 (6.1) | 29.7 (5.2) | 29.5 (5.5) |
Mean SF-36 PCS score (SD) | 41.3 (10.2) | 41.6 (8.4) | 41.5 (9.0) |
Mean SF-36 MCS score (SD) | 53.6 (11.3) | 53.6 (9.0) | 53.6 (9.8) |
Mean FIQR total score (SD), range 0 to 100 | 21.4 (15.8) | 19.4 (11.9) | 20.1 (13.3) |
Mean MAF global fatigue score (SD), range 1 to 50 | 21.4 (10.4) | 20.7 (9.7) | 21.0 (9.9) |
Mean BPI average pain score (SD), range 0 to 10 | 2.5 (1.3) | 2.3 (1.4) | 2.3 (1.4) |
Mean VAS pain score (SD), range 0 to 100 | 19.3 (11.6) | 16.6 (9.6) | 17.5 (10.3) |
Mean VAS pain score (SD), pre-milnacipran exposureb | 66.2 (14.7) | 65.4 (13.0) | 65.7 (13.6) |